Armata Pharmaceuticals, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Deborah L. Birx and CFO David House certified the June 30, 2026 quarterly report on Forms 31.1, 31.2, 32.1, and 32.2, affirming accuracy of financial statements, effectiveness of disclosure controls and internal controls, and compliance with SEC reporting requirements. No material weaknesses, deficiencies, or fraud were disclosed. Certifications dated August 12, 2026.
Why this rating
Routine mandatory SOX certifications; boilerplate filing exhibit with no substantive business changes, deals, or control issues disclosed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.